GRAMD4 Antikörper (full length)

Produktnummer ABIN7878318

Der Maus Monoklonal anti-GRAMD4 Antikörper wird verwendet zum Nachweis von GRAMD4 in Proben von Human. Er wurde validiert für FACS und IF.

Kurzübersicht für GRAMD4 Antikörper (full length) (ABIN7878318)

Target: GRAMD4 (GRAM Domain Containing 4 (GRAMD4))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser GRAMD4 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunofluorescence (IF)

Güteklasse: Carrier-free

Klon: PCRP-GRAMD4-1A10

Produktdetails anti-GRAMD4 Antikörper

Bindungsspezifität: full length

Verwendungszweck: GRAMD4 Antibody (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: Recombinant full-length human GRAMD4 protein was used as the immunogen for the GRAMD4 antibody.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the GRAMD4 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Aliquot the GRAMD4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu GRAMD4

Target: GRAMD4 (GRAM Domain Containing 4 (GRAMD4))

Andere Bezeichnung: GRAMD4

Hintergrund: The gene encoding GRAMD4 (GRAM domain-containing protein 4) maps to human chromosome 22, which houses over 500 genes and is the second smallest human chromosome. GRAMD4, also designated death-inducing protein (DIP), is a 578 amino acid mitochondrial membrane protein that acts as an essential mediator of the p53-independent E2F-1 death pathway, which is frequently found to be deregulated in several types of cancers. Overexpression of GRAMD4 results in a strong apoptotic response involving caspase-3 activation and cleavage of poly(ADP-ribose)-polymerase. GRAMD4 is expressed in lung and in primary lung squamous cell carcinoma (LSCC) and shows upregulation in mitochondria by E2F1 after addition of 4-hydroxytamoxifen. This evidence suggests that GRAMD4 may be a potential target for cancer therapies.

UniProt: Q6IC98